Data-Driven: The Strategic Intelligence Behind Every Frame
We Don't Create Videos. We Engineer Outcomes.
How Half a Million Dollars in Testing Changed Everything
When prospects ask us how we know our work drives commercial success, we don't show them our prettiest animations. We show them our data. Because after ten years of obsessive measurement and analysis, we've discovered that successful companies aren't just presenting better, they are deploying strategic assets across every touchpoint where investors, partners, and acquirers engage with their science.
For example, back in 2016, we were working with a client in the pharmaceutical reagent space who needed one thing, more sales. Not a video, not an animation, but actual revenue growth. So we created their campaign, then invested half a million dollars of their marketing budget testing every possible variable. We started in the US market, then systematically expanded globally, tracking performance metrics most studios don't even know exist.
The campaign ended up driving 60% of their total B2B sales revenue. Several years later, they were acquired by a Fortune 500 life sciences company.
"The number of leads that we have received increased once they took control of our online advertising. We are looking forward to repeating the process with other areas of our business now that we know it works so well."
David B. (CEO of B2B sales company)
But the campaign's success wasn't just about the video itself—it was about deployment intelligence. Knowing not just what to create but how to use it is what transforms a good video into a revenue driver.
.png)
Discovery Through Data: The 3D/2D Combo Innovation
Look at this image. This is real engagement data from one of our campaigns. 38,400 total plays. Real people watching.
See that massive drop by 14 seconds? Half your audience just left. This is the brutal reality nobody in our industry talks about because nobody else has this data. You spend months perfecting a production, getting the science exactly right, and 14 seconds in, half the people watching are gone.
Now look at the two-minute mark. Another drop. People lose patience. The attention window closes. These are just two of a number of key insights that changed everything about how we build our visuals.
Another example, some things work better in 3D. Molecular interactions. Binding mechanisms. Structural complexity. But other things kill engagement in 3D. Facts. Figures. Clinical data. These need clean 2D motion graphics for clarity and speed.
At first biomedical animation studios refused to mix them. They thought 2D was beneath them. Too simple. Not prestigious enough for their portfolios. We didn't care about prestige. We cared about results.
So we invented the 3D/2D Combo. Strategic 3D segments for molecular and cellular interactions. Clean 2D for everything else. Optimized around that 14-second hook and the two-minute attention window. We were the first ones to do this in biomedical animation. Then everyone started copying us. Because it works.
3D/2D Combo example below.
Every Decision Backed by Intelligence
Another example of data driving decisions: our own origin story. When launching our company, we analyzed search patterns and discovered that people were searching for "animation for biotech" but nobody had optimized for it. So we named ourselves Biotech Animated.
The result? Immediate top ranking for our chosen terms. We could have consulted The Hitchhiker's Guide for our company name. Instead, we let market research be our guide.
A few years later, everyone started copying us. Creating new service offerings and web pages especially for "biotech animation". Even targeting the phrase "biotech animated" in paid advertising.
Nonetheless, this analytical approach extends to everything we create. Before creating any content, we analyze trends, and competitive landscapes. We know which therapeutic areas respond to specific visual styles, what complexity level builds confidence versus confusion, and exactly where your production has maximum impact across all deployment channels.
Patterns Emerge from Deep Analysis
After analyzing hundreds of projects across every major therapeutic area—from antibody conjugation technologies to neurodegenerative diseases, from CAR-T therapies to enzymatic DNA synthesis—we've identified patterns that others miss. Platform technology companies require different narrative structures than single-asset biotechs. Immunotherapy stories demand different pacing than small molecule presentations. Cell therapy visualizations need different complexity thresholds than diagnostic technologies.
Every project adds to our strategic intelligence. Over 100 completed projects. More than $500 million in funding gained by our clients using our visuals as a key strategic asset. Tens of millions of dollars in tracked sales data from our campaigns, and several major 7-9 figure acquisitions of our clients. Engagement data from millions of users—not just views, but comprehensive behavioral analytics including scroll patterns, click-through rates, and conversion metrics.
Ready to Engineer Your Outcome?
Other studios treat biomedical animation like artwork. We treat it as a science.